Allergan Stock Price, News & Analysis (NYSE:AGN)

$171.68 0.74 (0.43 %)
(As of 12/15/2017 04:00 PM ET)
Previous Close$171.68
Today's Range$170.61 - $174.59
52-Week Range$160.07 - $256.80
Volume4.05 million shs
Average Volume3.02 million shs
Market Capitalization$56.85 billion
P/E Ratio11.09
Dividend Yield1.64%
Beta1.11

About Allergan (NYSE:AGN)

Allergan logoAllergan, Inc. is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. The Company operates in two segments: specialty pharmaceuticals and medical devices. The specialty pharmaceuticals segment produces products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy and retinal disease; Botox for therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth and prescription and OTC skin care products, and urologics products. The medical devices segment produces medical devices, including breast implants for augmentation, revision and reconstructive surgery and tissue expanders, and facial aesthetics products.

Receive AGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drugs - Generic
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNYSE:AGN
CUSIP01849010
Phone353-1435-7700

Debt

Debt-to-Equity Ratio0.40%
Current Ratio1.18%
Quick Ratio1.08%

Price-To-Earnings

Trailing P/E Ratio11.09
Forward P/E Ratio10.55
P/E Growth1.15

Sales & Book Value

Annual Sales$14.57 billion
Price / Sales3.92
Cash Flow$32.70 per share
Price / Cash5.25
Book Value$190.01 per share
Price / Book0.90

Profitability

Trailing EPS($22.50)
Net Income$14.97 billion
Net Margins-47.27%
Return on Equity8.00%
Return on Assets4.45%

Miscellaneous

Employees16,700
Outstanding Shares332,580,000

Allergan (NYSE:AGN) Frequently Asked Questions

What is Allergan's stock symbol?

Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

How often does Allergan pay dividends? What is the dividend yield for Allergan?

Allergan announced a quarterly dividend on Friday, October 27th. Stockholders of record on Friday, November 17th will be given a dividend of $0.70 per share on Friday, December 15th. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.63%. The ex-dividend date of this dividend is Thursday, November 16th. View Allergan's Dividend History.

How will Allergan's stock buyback program work?

Allergan declared that its board has authorized a stock buyback program on Tuesday, September 26th 2017, which allows the company to buyback $2,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to purchase up to 2.8% of its stock through open market purchases. Stock buyback programs are typically an indication that the company's leadership believes its stock is undervalued.

How were Allergan's earnings last quarter?

Allergan PLC. (NYSE:AGN) announced its earnings results on Wednesday, November, 1st. The company reported $4.15 EPS for the quarter, beating analysts' consensus estimates of $4.06 by $0.09. The business had revenue of $4.03 billion for the quarter, compared to the consensus estimate of $4.04 billion. Allergan had a positive return on equity of 8.00% and a negative net margin of 47.27%. The firm's quarterly revenue was up 11.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.32 EPS. View Allergan's Earnings History.

When will Allergan make its next earnings announcement?

Allergan is scheduled to release their next quarterly earnings announcement on Tuesday, February, 6th 2018. View Earnings Estimates for Allergan.

What guidance has Allergan issued on next quarter's earnings?

Allergan issued an update on its FY17 earnings guidance on Wednesday, November, 1st. The company provided EPS guidance of $16.15-16.45 for the period, compared to the Thomson Reuters consensus EPS estimate of $16.21. The company issued revenue guidance of $15.875-16.025 billion, compared to the consensus revenue estimate of $15.90 billion.

Where is Allergan's stock going? Where will Allergan's stock price be in 2017?

18 equities research analysts have issued twelve-month price targets for Allergan's shares. Their predictions range from $160.07 to $280.00. On average, they expect Allergan's stock price to reach $234.82 in the next year. View Analyst Ratings for Allergan.

What are Wall Street analysts saying about Allergan stock?

Here are some recent quotes from research analysts about Allergan stock:

  • 1. According to Zacks Investment Research, "Allergan boasts dominant growth franchises in several areas and is strengthening its product portfolio through strategic acquisitions. Key products like Botox and Linzess and new products such as Viberzi and Vraylar, are supporting sales growth. It also boasts a strong branded pipeline. Biosimilars also represent significant opportunity. However, while we remain optimistic about the company’s growth prospects, it is facing generic competition for legacy brands like Namenda and Asacol HD as well as patent challenges for some of the other products in its branded portfolio, which concerns us. Also, competition for key growth drivers, Restasis and Linzess, is an investor concern. Though Allergan’s shares have declined this year so far, they have performed better than the industry. Estimates have declined slightly ahead of the Q3 earnings release. The company has a mixed record of earnings surprises in recent quarters." (10/23/2017)
  • 2. Cantor Fitzgerald analysts commented, "Allergan announced mixed top-line results from its Phase 2b study of CVC for NASH. The Street was waiting for this, and the delay relative to Street expectations had been one reason the stock has been weak." (9/22/2017)
  • 3. Leerink Swann analysts commented, "AGN modestly beat our 4Q topline forecast (+1.3%) while Non-GAAP EPS beat our forecast by +3.8%. Given the 4Q strength of AGN's aesthetic franchises we're modestly raising our sales and EPS estimates." (2/9/2017)

Who are some of Allergan's key competitors?

Who owns Allergan stock?

Allergan's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Edgewood Management LLC (1.34%), Bank of New York Mellon Corp (1.03%), Baupost Group LLC MA (0.89%), Epoch Investment Partners Inc. (0.54%), Parnassus Investments CA (0.54%) and Legal & General Group Plc (0.52%). Company insiders that own Allergan stock include Brent L Saunders, Chris W Bodine, Christopher J Coughlin, Maria Teresa Hilado, Nesli Basgoz, Paul Bisaro and William Meury. View Institutional Ownership Trends for Allergan.

Who sold Allergan stock? Who is selling Allergan stock?

Allergan's stock was sold by a variety of institutional investors in the last quarter, including Parnassus Investments CA, Bessemer Group Inc., American Century Companies Inc., Mar Vista Investment Partners LLC, APG Asset Management N.V., Jackson Square Partners LLC, Morningstar Investment Services LLC and Los Angeles Capital Management & Equity Research Inc.. Company insiders that have sold Allergan company stock in the last year include Nesli Basgoz, Paul Bisaro and William Meury. View Insider Buying and Selling for Allergan.

Who bought Allergan stock? Who is buying Allergan stock?

Allergan's stock was bought by a variety of institutional investors in the last quarter, including Edgewood Management LLC, Baupost Group LLC MA, Asset Management One Co. Ltd., Point72 Asset Management L.P., Russell Investments Group Ltd., Iridian Asset Management LLC CT, Rothschild Asset Management Inc. and Cramer Rosenthal Mcglynn LLC. Company insiders that have bought Allergan stock in the last two years include Brent L Saunders, Chris W Bodine, Christopher J Coughlin and Maria Teresa Hilado. View Insider Buying and Selling for Allergan.

How do I buy Allergan stock?

Shares of Allergan can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Allergan's stock price today?

One share of Allergan stock can currently be purchased for approximately $171.68.

How big of a company is Allergan?

Allergan has a market capitalization of $56.85 billion and generates $14.57 billion in revenue each year. The company earns $14.97 billion in net income (profit) each year or ($22.50) on an earnings per share basis. Allergan employs 16,700 workers across the globe.

How can I contact Allergan?

Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 353-1435-7700 or via email at [email protected]


MarketBeat Community Rating for Allergan (AGN)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  920 (Vote Outperform)
Underperform Votes:  410 (Vote Underperform)
Total Votes:  1,330
MarketBeat's community ratings are surveys of what our community members think about Allergan and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Allergan (NYSE:AGN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.582.582.712.71
Ratings Breakdown: 0 Sell Rating(s)
8 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
8 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
17 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
17 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $235.71$245.29$281.24$278.40
Price Target Upside: 36.44% upside38.40% upside21.03% upside18.59% upside

Allergan (NYSE:AGN) Consensus Price Target History

Price Target History for Allergan (NYSE:AGN)

Allergan (NYSE:AGN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/12/2017Cantor FitzgeraldSet Price TargetHold$191.00LowView Rating Details
12/7/2017ArgusDowngradeBuy -> Hold$256.80 -> $160.07LowView Rating Details
12/6/2017Morgan StanleySet Price TargetBuy$200.00MediumView Rating Details
12/6/2017Wells Fargo & CompanyReiterated RatingBuyMediumView Rating Details
11/27/2017Leerink SwannReiterated RatingOutperform -> Outperform$237.00LowView Rating Details
11/2/2017Royal Bank of CanadaLower Price TargetOutperform -> Outperform$250.00 -> $221.00N/AView Rating Details
10/22/2017J P Morgan Chase & CoSet Price TargetBuy$275.00N/AView Rating Details
10/20/2017CowenSet Price TargetBuy$400.00 -> $280.00N/AView Rating Details
10/19/2017CitigroupLower Price TargetBuy$280.00 -> $240.00N/AView Rating Details
10/19/2017MizuhoDowngradeBuy -> Neutral$193.00 -> $193.00N/AView Rating Details
10/18/2017Edward JonesReiterated RatingBuy -> HoldN/AView Rating Details
10/18/2017Sanford C. BernsteinSet Price TargetBuy$296.00 -> $252.00N/AView Rating Details
10/17/2017Deutsche BankSet Price TargetBuy$251.00N/AView Rating Details
10/17/2017Credit Suisse GroupSet Price TargetOutperform$266.00 -> $243.00N/AView Rating Details
10/13/2017Piper Jaffray CompaniesSet Price TargetHold$227.00N/AView Rating Details
10/2/2017BarclaysReiterated RatingEqual WeightLowView Rating Details
5/10/2017Goldman Sachs GroupDowngradeBuy -> Neutral$262.00HighView Rating Details
12/23/2016Bank of AmericaReiterated RatingBuy$280.00N/AView Rating Details
11/21/2016William BlairReiterated RatingMarket PerformN/AView Rating Details
4/18/2016GuggenheimInitiated CoverageNeutralN/AView Rating Details
4/12/2016S&P Equity ResearchReiterated RatingBuyN/AView Rating Details
4/7/2016Raymond James FinancialLower Price TargetOutperform$317.00 -> $275.00N/AView Rating Details
4/7/2016Canaccord GenuityReiterated RatingBuyN/AView Rating Details
4/7/2016Susquehanna BancsharesDowngradePositive -> Neutral$345.00 -> $275.00N/AView Rating Details
4/5/2016NomuraReiterated RatingBuy$350.00 -> $330.00N/AView Rating Details
(Data available from 12/16/2015 forward)

Earnings

Allergan (NYSE:AGN) Earnings History and Estimates Chart

Earnings by Quarter for Allergan (NYSE:AGN)

Allergan (NYSE AGN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/6/2018N/AView Earnings Details
11/1/2017Q3 2017$4.06$4.15$4.04 billion$4.03 billionViewN/AView Earnings Details
8/3/2017Q2 2017$3.95$4.02$3.95 billion$4.01 billionViewListenView Earnings Details
5/9/2017Q1 2017$3.32$3.35$3.53 billion$3.57 billionViewListenView Earnings Details
2/8/2017Q416$3.76$3.90$3.77 billion$3.86 billionViewListenView Earnings Details
11/2/2016Q316$3.57$3.32$3.73 billion$3.62 billionViewListenView Earnings Details
8/8/2016Q216$3.34$3.35$4.10 billion$3.68 billionViewListenView Earnings Details
5/10/2016Q116$3.03$3.04$3.97 billion$3.80 billionViewListenView Earnings Details
2/22/2016Q415$3.36$3.41$4.20 billion$4.20 billionViewListenView Earnings Details
11/4/2015Q315$3.20$3.48$5.71 billion$4.10 billionViewN/AView Earnings Details
8/6/2015Q215$4.41$4.41$5.71 billion$5.76 billionViewN/AView Earnings Details
5/11/2015Q115$3.84$4.30$4.04 billion$4.23 billionViewListenView Earnings Details
2/18/2015Q414$3.67$3.91$3.84 billion$4.01 billionViewN/AView Earnings Details
11/5/2014Q414$1.83$2.17$1.90 billion$1.91 billionViewN/AView Earnings Details
11/5/2014Q314$3.10$3.19$3.63 billion$3.68 billionViewN/AView Earnings Details
8/5/2014Q314$1.76$1.78$1.78 billion$1.79 billionViewListenView Earnings Details
8/5/2014Q214$3.36$3.42$2.55 billion$2.67 billionViewN/AView Earnings Details
7/21/2014Q214$1.44$1.51$1.77 billion$1.83 billionViewN/AView Earnings Details
4/30/2014Q114$1.13$1.18$1.60 billion$1.65 billionViewN/AView Earnings Details
4/30/2014Q114$3.23$3.49$2.59 billion$2.66 billionViewListenView Earnings Details
2/20/2014Q413$3.05$3.17$2.68 billion$2.78 billionViewListenView Earnings Details
2/4/2014Q413$1.34$1.12$1.65 million$1.66 millionViewN/AView Earnings Details
10/29/2013Q313$1.20$1.23$1.53 billion$1.23 billionViewListenView Earnings Details
10/29/2013Q313$2.09$2.09$2.04 billion$2.01 billionViewListenView Earnings Details
7/31/2013Q2 2013$1.20$1.22$1.56 billion$1.60 billionViewN/AView Earnings Details
7/25/2013Q2 2013$2.00$2.01$1.99 billion$1.99 billionViewListenView Earnings Details
5/2/2013Q1 2013$1.86$1.99$1.97 billion$1.90 billionViewListenView Earnings Details
5/1/2013Q1 2013$0.96$0.98$1.44 billion$1.46 billionViewN/AView Earnings Details
2/19/2013Q4 2012$1.53$1.59$1.74 million$1.75 billionViewListenView Earnings Details
2/5/2013Q4 2012$1.20$1.15$1.51 million$1.48 millionViewN/AView Earnings Details
10/30/2012Q312$1.04$1.06$1.43 billion$1.39 billionViewN/AView Earnings Details
8/1/2012$1.06$1.07ViewN/AView Earnings Details
5/2/2012$0.87$0.86ViewN/AView Earnings Details
2/2/2012$1.00$1.00ViewN/AView Earnings Details
10/26/2011$0.90$0.92ViewN/AView Earnings Details
8/3/2011$0.95$0.96ViewN/AView Earnings Details
5/4/2011$0.74$0.77ViewN/AView Earnings Details
2/2/2011$0.89$0.88ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Allergan (NYSE:AGN) Earnings Estimates

2017 EPS Consensus Estimate: $16.29
2018 EPS Consensus Estimate: $15.04
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$3.33$3.55$3.44
Q2 20172$4.00$4.07$4.04
Q3 20173$4.03$4.16$4.09
Q4 20174$4.61$4.84$4.72
Q1 20181$3.42$3.42$3.42
Q2 20181$3.82$3.82$3.82
Q3 20181$3.58$3.58$3.58
Q4 20181$4.22$4.22$4.22
(Data provided by Zacks Investment Research)

Dividends

Allergan (NYSE:AGN) Dividend Information

Most Recent Dividend:12/15/2017
Annual Dividend:$2.80
Dividend Yield:1.63%
Dividend Growth:0.00% (3 Year Average)
Payout Ratio:-12.44% (Trailing 12 Months of Earnings)
17.21% (Based on This Year's Estimates)
17.52% (Based on Next Year's Estimates)
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Allergan (NYSE:AGN)

Allergan (NYSE:AGN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/27/2017quarterly$0.701.58%11/16/201711/17/201712/15/2017
8/2/2017Quarterly$0.701.12%8/16/20178/18/20179/15/2017
5/5/2017quarterly$0.700.01%5/16/20175/18/20176/15/2017
11/2/2016quarterly$0.702/24/20172/28/20173/28/2017
2/4/2015quarterly$0.050.09%2/5/20152/9/20153/20/2015
10/27/2014quarterly$0.0511/20/201412/11/2014
7/28/2014quarterly$0.050.12%8/13/20148/15/20149/5/2014
5/7/2014quarterly$0.050.12%5/21/20145/23/20146/13/2014
2/5/2014quarterly$0.050.17%2/26/20142/28/20143/21/2014
10/30/2013quarterly$0.050.22%11/18/201311/20/201312/11/2013
7/31/2013quarterly$0.050.22%8/20/20138/22/20139/12/2013
5/2/2013quarterly$0.050.2%5/21/20135/23/20136/13/2013
2/6/2013quarterly$0.050.18%2/26/20132/28/20133/21/2013
(Data available from 1/1/2013 forward)

Insider Trades

Allergan (NYSE AGN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.36%
Institutional Ownership Percentage: 81.34%
Insider Trades by Quarter for Allergan (NYSE:AGN)
Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Allergan (NYSE AGN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/7/2017Chris W. BodineDirectorBuy3,030$164.77$499,253.10View SEC Filing  
12/6/2017Brent L. SaundersChairmanBuy4,600$164.74$757,804.00View SEC Filing  
12/5/2017Christopher J. CoughlinDirectorBuy10,000$163.30$1,633,000.00View SEC Filing  
12/1/2017William MeuryInsiderSell11,807$173.89$2,053,119.23View SEC Filing  
5/18/2017Nesli BasgozDirectorSell1,889$220.45$416,430.05View SEC Filing  
3/2/2017Paul BisaroDirectorSell70,000$246.68$17,267,600.00View SEC Filing  
12/8/2016Nesli BasgozDirectorSell500$188.72$94,360.00View SEC Filing  
11/21/2016Brent L. SaundersCEOBuy5,250$189.13$992,932.50View SEC Filing  
11/11/2016Maria Teresa HiladoCFOBuy1,422$210.64$299,530.08View SEC Filing  
6/2/2016Maria Teresa HiladoCFOBuy661$241.57$159,677.77View SEC Filing  
5/11/2016Nesli BasgozDirectorSell459$225.10$103,320.90View SEC Filing  
12/7/2015Nesli BasgozDirectorSell2,300$312.96$719,808.00View SEC Filing  
8/24/2015Paul BisaroChairmanBuy1,000$297.42$297,420.00View SEC Filing  
8/21/2015Brent L SaundersCEOBuy1,000$301.94$301,940.00View SEC Filing  
6/9/2015Nesli BasgozDirectorSell2,200$297.89$655,358.00View SEC Filing  
11/26/2014William MeuryInsiderSell4,550$269.14$1,224,587.00View SEC Filing  
9/8/2014Albert Paonessa IIIInsiderSell6,642$230.49$1,530,914.58View SEC Filing  
4/22/2014Scott ShermanEVPSell14,500$155.82$2,259,390.00View SEC Filing  
2/21/2014Louis Lavigne, Jr.DirectorSell5,400$125.79$679,266.00View SEC Filing  
2/19/2014Dawn HudsonDirectorSell4,200$126.35$530,670.00View SEC Filing  
2/19/2014Jeffrey EdwardsCFOSell38,900$126.39$4,916,571.00View SEC Filing  
2/19/2014Raymond DiradoorianEVPSell23,000$126.66$2,913,180.00View SEC Filing  
2/18/2014Scott ShermanEVPSell5,001$125.74$628,825.74View SEC Filing  
1/14/2014Scott WhitcupVPSell42,000$117.80$4,947,600.00View SEC Filing  
12/27/2013Julian GangolliVPSell52,500$110.05$5,777,625.00View SEC Filing  
12/20/2013Scott WhitcupVPSell33,000$108.80$3,590,400.00View SEC Filing  
10/15/2013Trevor JonesDirectorSell2,000$90.14$180,280.00View SEC Filing  
9/16/2013Albert HummelDirectorSell6,200$137.81$854,422.00View SEC Filing  
9/16/2013Trevor JonesDirectorSell2,000$89.78$179,560.00View SEC Filing  
9/4/2013George Fred WilkinsonInsiderSell16,749$138.00$2,311,362.00View SEC Filing  
9/4/2013Jack MichelsonDirectorSell6,064$139.54$846,170.56View SEC Filing  
8/29/2013David BuchenInsiderSell10,000$135.56$1,355,600.00View SEC Filing  
8/26/2013Albert HummelDirectorSell40,000$134.44$5,377,600.00View SEC Filing  
8/20/2013Paul BisaroCEOSell50,000$135.30$6,765,000.00View SEC Filing  
8/15/2013Albert Paonessa IIIInsiderSell5,476$135.89$744,133.64View SEC Filing  
8/15/2013Trevor JonesDirectorSell2,000$89.89$179,780.00View SEC Filing  
8/14/2013R Todd JoyceCFOSell15,000$137.98$2,069,700.00View SEC Filing  
8/13/2013Albert HummelDirectorSell10,000$133.85$1,338,500.00View SEC Filing  
8/12/2013Cathy KlemaDirectorSell1,667$133.03$221,761.01View SEC Filing  
8/12/2013David BuchenInsiderSell17,000$133.03$2,261,510.00View SEC Filing  
8/9/2013Ronald TaylorDirectorSell5,000$135.14$675,700.00View SEC Filing  
8/6/2013Jeffrey EdwardsCFOSell69,200$91.17$6,308,964.00View SEC Filing  
8/5/2013Charles EbertVPSell8,244$136.25$1,123,245.00View SEC Filing  
8/5/2013Michel FeldmanDirectorSell10,000$136.94$1,369,400.00View SEC Filing  
8/2/2013Robert StewartInsiderSell14,564$136.02$1,980,995.28View SEC Filing  
7/15/2013Trevor M JonesDirectorSell2,000$91.15$182,300.00View SEC Filing  
6/17/2013Trevor M JonesDirectorSell2,000$101.25$202,500.00View SEC Filing  
5/15/2013Trevor M JonesDirectorSell2,000$103.40$206,800.00View SEC Filing  
5/9/2013Jeffrey L EdwardsCFOSell84,000$103.49$8,693,160.00View SEC Filing  
3/14/2013Charles M MayrInsiderSell1,000$91.77$91,770.00View SEC Filing  
3/12/2013Michael J FedidaDirectorSell8,000$89.00$712,000.00View SEC Filing  
11/26/2012Trevor M JonesDirectorSell2,500$91.30$228,250.00View SEC Filing  
10/5/2012David E I PyottCEOSell616,300$93.73$57,765,799.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Allergan (NYSE AGN) News Headlines

Source:
DateHeadline
John Griffin: A Former Tiger Cub"s Wavering FortunesJohn Griffin: A Former Tiger Cub"s Wavering Fortunes
finance.yahoo.com - December 15 at 3:19 PM
A ‘Better Botox’ May Target Millenials, Men and Hesitant WomenA ‘Better Botox’ May Target Millenials, Men and Hesitant Women
finance.yahoo.com - December 15 at 11:12 AM
Allergan PLC. (AGN) Receives Average Recommendation of "Buy" from BrokeragesAllergan PLC. (AGN) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - December 15 at 3:56 AM
Notable Thursday Option Activity: AGN, TIF, EMNNotable Thursday Option Activity: AGN, TIF, EMN
www.nasdaq.com - December 14 at 3:19 PM
Israeli drugmaker Teva to cut quarter of global work forceIsraeli drugmaker Teva to cut quarter of global work force
marketbeat.com - December 14 at 11:45 AM
Analyzing NephroGenex (NRXGQ) and Allergan (AGN)Analyzing NephroGenex (NRXGQ) and Allergan (AGN)
www.americanbankingnews.com - December 14 at 7:16 AM
Ease Those Frown Lines: Revances Impact On Allergan Overblown - Seeking AlphaEase Those Frown Lines: Revance's Impact On Allergan Overblown - Seeking Alpha
seekingalpha.com - December 14 at 6:25 AM
U.S. appeals court vacates conviction of drug distributor over BotoxU.S. appeals court vacates conviction of drug distributor over Botox
finance.yahoo.com - December 14 at 6:25 AM
Allergan (AGN) and NephroGenex (NRXGQ) Financial SurveyAllergan (AGN) and NephroGenex (NRXGQ) Financial Survey
www.americanbankingnews.com - December 13 at 5:38 PM
Woman-Led Drybar For Botox Chain Alchemy 43 Grows -- With Drybar Founders BackingWoman-Led 'Drybar For Botox' Chain Alchemy 43 Grows -- With Drybar Founders' Backing
finance.yahoo.com - December 13 at 3:22 PM
Revance will wait to seek backing for Botox-rivalRevance will wait to seek backing for Botox-rival
www.reuters.com - December 13 at 3:19 PM
Allergan Inks Deal to Buy Texas-Based Repros TherapeuticsAllergan Inks Deal to Buy Texas-Based Repros Therapeutics
www.zacks.com - December 13 at 3:19 PM
Allergan (AGN) vs. NephroGenex (NRXGQ) Head to Head ReviewAllergan (AGN) vs. NephroGenex (NRXGQ) Head to Head Review
www.americanbankingnews.com - December 13 at 11:16 AM
Allergan (AGN) Receives FDA Clearance For CoolSculpting Treatment to Improve Appearance of Lax Tissue in Double ... - StreetInsider.comAllergan (AGN) Receives FDA Clearance For CoolSculpting Treatment to Improve Appearance of Lax Tissue in Double ... - StreetInsider.com
www.streetinsider.com - December 12 at 3:18 PM
Cantor Fitzgerald Reiterates "$191.00" Price Target for Allergan (AGN)Cantor Fitzgerald Reiterates "$191.00" Price Target for Allergan (AGN)
www.americanbankingnews.com - December 12 at 12:46 PM
Allergan to buy Woodlands-based drug companyAllergan to buy Woodlands-based drug company
finance.yahoo.com - December 12 at 11:12 AM
Allergan Receives FDA Clearance For the CoolSculpting® Treatment To Improve Appearance Of Lax Tissue In The Double ChinAllergan Receives FDA Clearance For the CoolSculpting® Treatment To Improve Appearance Of Lax Tissue In The Double Chin
finance.yahoo.com - December 12 at 11:12 AM
Zacks: Brokerages Anticipate Allergan PLC. (AGN) Will Announce Quarterly Sales of $4.28 BillionZacks: Brokerages Anticipate Allergan PLC. (AGN) Will Announce Quarterly Sales of $4.28 Billion
www.americanbankingnews.com - December 12 at 9:46 AM
Repros Therapeutics (RPRX) to be Acquired by Allergan (AGN) for $0.67/Share - StreetInsider.comRepros Therapeutics (RPRX) to be Acquired by Allergan (AGN) for $0.67/Share - StreetInsider.com
www.streetinsider.com - December 12 at 7:22 AM
Allergan to acquire Repros for $0.67 per shareAllergan to acquire Repros for $0.67 per share
seekingalpha.com - December 12 at 7:21 AM
Allergan: Is Revance The Botox Killer? - Seeking AlphaAllergan: Is Revance The Botox Killer? - Seeking Alpha
seekingalpha.com - December 11 at 4:22 PM
Allergan on the Street: Analyst Recommendations This DecemberAllergan on the Street: Analyst Recommendations This December
finance.yahoo.com - December 11 at 11:24 AM
What Are Analysts Estimating for Allergan Today?What Are Analysts Estimating for Allergan Today?
finance.yahoo.com - December 11 at 11:24 AM
Allergan - I Am Allergic To Aggressive Practices - Seeking AlphaAllergan - I Am Allergic To Aggressive Practices - Seeking Alpha
seekingalpha.com - December 11 at 7:00 AM
Weekly Top Insider Buys Highlight for the Week of Dec. 8Weekly Top Insider Buys Highlight for the Week of Dec. 8
finance.yahoo.com - December 10 at 10:33 AM
3 Drug/Biotech Stocks Up More Than 10% This Week3 Drug/Biotech Stocks Up More Than 10% This Week
finance.yahoo.com - December 8 at 3:18 PM
ETFs with exposure to Allergan Plc : December 8, 2017ETFs with exposure to Allergan Plc : December 8, 2017
finance.yahoo.com - December 8 at 3:18 PM
Behind Allergan’s Revenues in 3Q17Behind Allergan’s Revenues in 3Q17
finance.yahoo.com - December 8 at 10:51 AM
Inside Allergan’s US Specialized Therapeutics in 3Q17Inside Allergan’s US Specialized Therapeutics in 3Q17
finance.yahoo.com - December 8 at 10:51 AM
Inside Allergan’s US General Medicines in 3Q17Inside Allergan’s US General Medicines in 3Q17
finance.yahoo.com - December 8 at 10:51 AM
Breaking down Allergan’s Business Segments in 3Q17Breaking down Allergan’s Business Segments in 3Q17
finance.yahoo.com - December 8 at 7:35 AM
Cramer's lightning round: Energy Transfer Partners is wor...Cramer's lightning round: Energy Transfer Partners is wor...
finance.yahoo.com - December 8 at 6:34 AM
Cramer Remix: Yes, Allergan is the anti-bitcoinCramer Remix: Yes, Allergan is the anti-bitcoin
www.cnbc.com - December 7 at 7:28 PM
Chris W. Bodine Purchases 3,030 Shares of Allergan PLC. (AGN) StockChris W. Bodine Purchases 3,030 Shares of Allergan PLC. (AGN) Stock
www.americanbankingnews.com - December 7 at 5:28 PM
Botox Competition Spurs Argus To Downgrade AllerganBotox Competition Spurs Argus To Downgrade Allergan
www.benzinga.com - December 7 at 3:19 PM
Allergan Plc (AGN) Chairman, President and CEO Brent L Saunders Bought $757,804 of SharesAllergan Plc (AGN) Chairman, President and CEO Brent L Saunders Bought $757,804 of Shares
finance.yahoo.com - December 7 at 3:19 PM
Allergan (AGN) Rating Lowered to Hold at ArgusAllergan (AGN) Rating Lowered to Hold at Argus
www.americanbankingnews.com - December 7 at 9:14 AM
Allergan Ends Positive After Sell-Off; Walgreens, Freds Make Moves -- ICYMI - TheStreet.comAllergan Ends Positive After Sell-Off; Walgreens, Fred's Make Moves -- ICYMI - TheStreet.com
www.thestreet.com - December 7 at 7:26 AM
Allergan Ends Positive After Sell-Off; Walgreens, Freds Make Moves -- ICYMIAllergan Ends Positive After Sell-Off; Walgreens, Fred's Make Moves -- ICYMI
finance.yahoo.com - December 7 at 6:37 AM
Allergan (AGN) Lowered to Buy at VetrAllergan (AGN) Lowered to Buy at Vetr
www.americanbankingnews.com - December 7 at 12:48 AM
TheStreet Downgrades Allergan (AGN) to D+TheStreet Downgrades Allergan (AGN) to D+
www.americanbankingnews.com - December 6 at 10:38 PM
Allergan plc (AGN)Allergan plc (AGN)
seekingalpha.com - December 6 at 3:18 PM
Allergan PLC. (AGN) Chairman Acquires $757,804.00 in StockAllergan PLC. (AGN) Chairman Acquires $757,804.00 in Stock
www.americanbankingnews.com - December 6 at 2:38 PM
Allergan (AGN) Earns "Buy" Rating from Wells Fargo & CompanyAllergan (AGN) Earns "Buy" Rating from Wells Fargo & Company
www.americanbankingnews.com - December 6 at 12:40 PM
Allergan (AGN) Given a $200.00 Price Target by Morgan Stanley AnalystsAllergan (AGN) Given a $200.00 Price Target by Morgan Stanley Analysts
www.americanbankingnews.com - December 6 at 12:40 PM
Fine Lines: Why Allergans Botox Aint BeatFine Lines: Why Allergan's Botox Ain't Beat
finance.yahoo.com - December 6 at 11:05 AM
Allergan: Loss Of Drug Exclusivity Extrapolated Too Far - Seeking AlphaAllergan: Loss Of Drug Exclusivity Extrapolated Too Far - Seeking Alpha
seekingalpha.com - December 6 at 6:46 AM
Allergan plays down Revance data - Seeking AlphaAllergan plays down Revance data - Seeking Alpha
seekingalpha.com - December 6 at 6:46 AM
How Ackman Hopes to Beat Insider-Trading Lawsuit: QuickTake Q&AHow Ackman Hopes to Beat Insider-Trading Lawsuit: QuickTake Q&A
finance.yahoo.com - December 6 at 6:46 AM
NephroGenex (NRXGQ) & Allergan (AGN) Head-To-Head AnalysisNephroGenex (NRXGQ) & Allergan (AGN) Head-To-Head Analysis
www.americanbankingnews.com - December 5 at 7:52 PM

SEC Filings

Allergan (NYSE:AGN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Allergan (NYSE:AGN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Allergan (NYSE AGN) Stock Chart for Saturday, December, 16, 2017

Loading chart…

This page was last updated on 12/16/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.